PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DB23FC2FQ4561007327!ticovac 2.4 MCG 0.5 ML syringe 0.5ml — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DB20D7066. PoP ended May 23, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Amerisourcebergen Drug Corp

Recipient

May 23, 2023

PoP end

$139K

Obligated

$139K

Potential

424210

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

Federal

Contract numberSPE2DB23FC2FQ

Also listed asSPE2DB20D7066-SPE2DB23FC2FQ

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentAmerisourcebergen Drug Corp

CAGE1XUY5

UEIKABZK8W6PQT3

NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DB20D7066

Place of performanceCONSHOHOCKEN PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMay 22, 2023

PoP end (current)May 23, 2023

Obligated$139K

Current value$139K

Potential value$139K

4561007327!TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $139K ($139K obligated). Current period of performance ends May 23, 2023. Place of performance: CONSHOHOCKEN PA.

4561007327!TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML

Recompete timing

Public

● Past PoP end (1186 days ago)

Current PoP ended May 23, 2023 (1186 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies

Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%

Open full company profile →

Related awards

Same parent · incumbent

36C77026P0121

DROSPIRENONE

$321K

Sep 27, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DB23FC2FQ?

SPE2DB23FC2FQ (4561007327!ticovac 2.4 MCG 0.5 ML syringe 0.5ml) is a Dla Troop Support award with a potential value of $139K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DB23FC2FQ?

Dla Troop Support awarded SPE2DB23FC2FQ to Amerisourcebergen Drug Corp (potential $139K).

Who is the incumbent on SPE2DB23FC2FQ?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends May 23, 2023.

When does Amerisourcebergen Drug Corp’s SPE2DB23FC2FQ come up for recompete?

SCOUT tracks a period-of-performance end of May 23, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 11, 2026 · refreshed monthlyLatest procurement action May 22, 2023